Bacteroides ovatus for relieving endotoxin infection and application thereof
US11419905B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 28, 2020 |
| Grant date | Aug 23, 2022 |
| Priority date | — |
| Expiry date | Oct 28, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12R2001/01
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure discloses Bacteroides ovatus for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides ovatus CCFM1021 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of mice infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides ovatus CCFM1021 for relieving endotoxin infection has broad application prospects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.